Emergent BioSolutions CDMO
400 Professional Drive, Suite 400
Gaithersburg, MD 20879
T: +1 800 441 4225 (in the US)
T: +1 240 631 3200 (outside the US)
E: cdmo@ebsi.com
W: https://emergentCDMO.com
LinkedIn: https://www.linkedin.com/showcase/emergent-biosolutions-cdmo

Perfecting Your Formula

Emergent CDMO is dedicated to helping pharma and biotech innovators bring lifesaving therapies to patients from around the world. Our nine development and manufacturing sites in North America and Europe can support early to late stage production of biotherapeutics and vaccines. Whether you’re looking for initial process development support, small volumes of material for clinical trials, or large-scale production for a global commercial therapy, our experienced CDMO team is ready to serve as your trusted guide from molecule to market.

Technologies & Platforms for Every Strategy

We support a broad portfolio of preclinical through commercial programs with experience in a wide range of platforms and technologies including mammalian, microbial, viral, plasma, and gene therapies.

Development Services
-Process Development
-Analytical Development
-Formulation Development
-Non-GMP Lab-Scale Manufacturing

Drug Substance Manufacturing
-Upstream & Downstream Processing
-Single-Use Platforms (up to 4000L)

Drug Product Manufacturing
-Vials, Prefilled Syringes, and Cartridges
-Lyophilization Services
-High Containment Filling (viral and non-viral)
-Packaging & Labeling

Wherever you are in your journey, whatever challenges you face, our team of experts and resources are ready to go to work for you. Let’s get started with your next clinical or commercial candidate. Your new formula for success awaits.

About Us

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through Emergent’s specialty products and contract development and manufacturing services, Emergent is dedicated to providing solutions that address public health threats. Through social responsibility, Emergent aims to build healthier and safer communities. Emergent aspires to deliver peace of mind to its patients and customers so they can focus on what’s most important in their lives. In working together, Emergent envisions protecting or enhancing 1 billion lives by 2030.

Recent Webinars

Enhancing our Capabilities for Aseptic Fill/Finish Processing: Introducing the Groninger FlexPro 50

Hear from Emergent leaders and technical experts as they discuss the features of the Groninger® FlexPro 50 fill line and the advantages of utilizing isolator-based technology for aseptic processing of pre-sterilized syringes, cartridges, and vials.